Evaxion Biotech (EVAX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evaxion Biotech, a clinical-stage TechBio company, is set to reveal its Q2 2024 financial outcomes and provide a business update on August 14, before the Nasdaq-CM market opens. The company, known for leveraging its AI-Immunology platform to create immunotherapies for cancer and infectious diseases, will also host a public conference call and webcast to discuss the results and field questions. Evaxion’s progress is closely watched as it aims to transform patient care with its innovative AI-driven vaccine pipeline.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.